Virginia M Klimek

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia
    Virginia M Klimek
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Hematol 20:137-43. 2013
  2. doi request reprint Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
    Virginia M Klimek
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Res 36:1093-7. 2012
  3. doi request reprint Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia
    Virginia M Klimek
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Leuk Res 36:570-4. 2012
  4. doi request reprint Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    Virginia M Klimek
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:826-32. 2008
  5. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
  6. pmc Progression of RAS-mutant leukemia during RAF inhibitor treatment
    Margaret K Callahan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 367:2316-21. 2012
  7. pmc Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia
    Alan H Shih
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Haematologica 98:908-12. 2013
  8. doi request reprint Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia
    Muhamed Baljevic
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, New York, NY 10065, USA
    Acta Haematol 129:48-54. 2013
  9. ncbi request reprint Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Azra Raza
    Rush University Medical Center, Chicago, IL, USA
    Blood 111:86-93. 2008

Collaborators

Detail Information

Publications9

  1. doi request reprint Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia
    Virginia M Klimek
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Hematol 20:137-43. 2013
    ..This review describes available treatments and recent advances that may influence the clinical management of t-MDS/AML...
  2. doi request reprint Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
    Virginia M Klimek
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Res 36:1093-7. 2012
    ..We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS...
  3. doi request reprint Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia
    Virginia M Klimek
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Leuk Res 36:570-4. 2012
    ..One patient had grade 3/4 elevations in AST/ALT. This study suggests that sodium salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity or hepatotoxicity...
  4. doi request reprint Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes
    Virginia M Klimek
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:826-32. 2008
    ....
  5. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
    ..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
  6. pmc Progression of RAS-mutant leukemia during RAF inhibitor treatment
    Margaret K Callahan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 367:2316-21. 2012
    ..Exposure to vemurafenib induced hyperactivation of ERK signaling and proliferation of the leukemic cell population, an effect that was reversed on drug withdrawal...
  7. pmc Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia
    Alan H Shih
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Haematologica 98:908-12. 2013
    ..5%). Cases with a TP53 mutation or loss of the TP53 locus had a worse overall survival compared to those with wild-type TP53 (8.8 vs. 37.4 months; P=0.0035)...
  8. doi request reprint Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia
    Muhamed Baljevic
    Department of Medicine, New York Presbyterian Hospital Weill Cornell Medical Center, New York, NY 10065, USA
    Acta Haematol 129:48-54. 2013
    ....
  9. ncbi request reprint Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Azra Raza
    Rush University Medical Center, Chicago, IL, USA
    Blood 111:86-93. 2008
    ..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...